"...ngio was valued at breast for 350 million back in interim phase 2 now that 10 year data end is out significant and positive, plus big benefit to late stage patients, that goes up hugely, merck partnership, even more..."
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
